CJC-1295 (no DAC): Research Applications
$25.20 · Free BAC water + free U.S. shipping · Same-day dispatch before 2 PM ET · FOR RESEARCH USE ONLY
Buy CJC (no DAC) Peptide 5mgResearch Applications
CJC-1295 (no DAC) / Modified GRF(1-29) is a tetrasubstituted GHRH(1-29) analog. FDA's December 2024 PCAC briefing identified no published clinical or preclinical efficacy studies for this specific substance; published work is analytical/forensic (Henninge 2010; Hartvig 2014).[9][1][3]
Analytical & Forensic Applications
CJC-1295 (no DAC) has been a subject of forensic and anti-doping research. Henninge et al. (2010) and Hartvig et al. (2014) developed LC-MS/MS methods to identify Modified GRF 1-29 in seized pharmaceutical preparations, confirming its widespread distribution in the grey market. These analytical methods also serve as the basis for WADA anti-doping testing protocols.[1][3][13]
“(2006)J Clin Endocrinol MetabHealthy human adults; CJC-1295 with DACGH and IGF-1 endpoints and half-life reported.”
References
- Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis, 2(11-12), 647-650, 2010.
- Soule S, King JA, Millar RP. The Journal of Clinical Endocrinology and Metabolism, 79(4), 1208-1211, 1994.
- Hartvig RA, Holm NB, Dalsgaard PW, Reitzel LA, Müller IB, Linnet K. Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007-2013. Scandinavian Journal of Forensic Science, 20(2), 42-49, 2014.
- Jetté L, et al. Endocrinology, 146(7), 3052-3058, 2005.
- Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH. Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochemical and Biophysical Research Communications, 119(1), 265-272, 1984.
- Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance Use & Misuse, 51(1), 73-84, 2016.
- Sigalos JT, Pastuszak AW. Sexual Medicine Reviews, 6(1), 45-53, 2018.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805, 2006.
- Food and Drug Administration. FDA Evaluation of CJC-1295 Related Bulk Drug Substances. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024.
- Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting. Center for Drug Evaluation and Research, December 4, 2024.
- World Anti-Doping Agency. The 2024 Prohibited List: International Standard. World Anti-Doping Code, 2024.
- Sinha DK, Balasubramanian A, Tatem AJ, Kovac JR, Pastuszak AW, Lipshultz LI. Translational Andrology and Urology, 9(Suppl 2), S149-S159, 2020.
- Fabresse N, Grassin-Delyle S, Etting I, Alvarez JC. Identification of a GHRH peptide analogue, the CJC-1295, using LC-HRMS/MS. Toxicologie Analytique et Clinique, 29(2), 205-211, 2017.
- Ben-Shlomo A, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. The Journal of Clinical Investigation, 130(11), 5738-5755, 2020.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797, 2006.
- Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11-12), 1871-1887, 2021.
Related Research Questions
Related research
Browse all research guides in the Peptide Research Library →Want the complete research review?
Buy CJC (no DAC) Peptide 5mg→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.